Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT06049095
PHASE1

A Phase 1 Single and Multiple Ascending Dose Study of LTG-001 Administered Orally in Healthy Participants

Sponsor: Latigo Biotherapeutics

View on ClinicalTrials.gov

Summary

This is a sequential, randomized, double-blind, placebo-controlled Phase 1 single (SAD) and multiple (MAD) ascending dose study to evaluate the safety, tolerability, and pharmacokinetics (PK) of orally or intravenously administered LTG-001 in healthy male and female participants

Official title: A Sequential, Randomized, Double-Blind, Placebo-Controlled, Phase 1 Single and Multiple Ascending Dose Study of LTG-001 Administered Orally of Intravenously to Evaluate the Safety, Tolerability, and Pharmacokinetics in Healthy Male and Female Participants 18 to 55 Years of Age

Key Details

Gender

All

Age Range

18 Years - 55 Years

Study Type

INTERVENTIONAL

Enrollment

204

Start Date

2023-10-17

Completion Date

2026-04-28

Last Updated

2026-01-23

Healthy Volunteers

Yes

Conditions

Interventions

DRUG

LTG-001

Oral doses

DRUG

Placebo

Oral doses

Locations (1)

Clinical Research Unit

Christchurch, New Zealand